DGAP-News: PAION AG / Key word(s): Change of Personnel
06.12.2017 / 14:00
The issuer is solely responsible for the content of this announcement.
JÜRGEN BECK, MD APPOINTED AS CHIEF DEVELOPMENT OFFICER AT PAION AG
– New CDO brings wealth of experience in international product developments
Aachen (Germany), 06 December 2017 – PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), today announces that Dr. Jürgen Beck has been appointed by the Supervisory Board as a new member of the Management Board of PAION AG and will be Chief Development Officer with effect from 1 January 2018. Dr. Beck has been working for PAION as a consultant since beginning of 2017. Within the Management Board, he will be responsible for product development in the future, in particular for the remimazolam development program in procedural sedation in the U.S. and for the EU Phase III program in general anesthesia.
Dr. Beck has over 25 years of experience in the European pharma business, with positions held in various drug development projects. As a graduated physician and having a diploma in business administration, he held inter alia various senior management positions at Synthélabo for many years, was longtime Managing Director of the contract research organization Monitoring Force GmbH, Senior Vice President of Medical Affairs at Epigenomics and Vice President of Clinical Operations Europe at InterMune International AG.
Dr. Jörg Spiekerkötter, Chairman of the Supervisory Board of PAION AG, commented: “With many years of international expertise in product development, Dr. Beck is an excellent addition to the Management Board of PAION AG. Dr. Beck will move PAION further forward on its successful path and will accompany key steps towards U.S. approval and further development of remimazolam in Europe.”
“On behalf of the management, I welcome Dr. Jürgen Beck as new CDO. Together, we share the vision of moving PAION to an acknowledged “PAIONeer” in sedation and anesthesia for which Dr. Beck has already inspired new momentum“, Dr. Wolfgang Söhngen, CEO of PAION AG, commented.
A photo and the CV of Dr. Jürgen Beck can be found at http://www.paion.com/company/about-paion/management/.
PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom).
PAION’s vision is to become an acknowledged “PAIONeer” in sedation and anesthesia.
06.12.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|